Biologics represent a wide variety of complex large-molecule drug products and present different development challenges than small-molecule drugs (NCEs). While the goals for safety evaluation are similar to traditional NCE products, the approach is generally very different for biologics.
In this webinar, Dr. Kirsty Harper, Director of Biopharmaceutical at Envigo, discusses the key considerations and approaches required for the assessment of biopharmaceutical products in ‘Introduction to non-clinical safety assessment of biologics.‘
This informative webinar will:
- Explore an overview of biologics and what makes them different to small molecule drugs
- Discuss species selection and general considerations for the design of effective safety studies
- Review product-specific pharmacology and its importance in safety assessment
Click here for more information on Envigo.